The Childrens Cancer Group (CCG) is a research organization of more than 2000 clinical and laboratory specialists in the cancers of Children, located at 112 pediatric medical centers in the United States, Canada, and Australia. Its purpose is to ultimately eliminate cancer as a major problem among children, by cooperative conduct of research, including: 1) Clinical trials of new multimodality treatment strategies; 2) Clinical and laboratory studies of new anticancer agents; 3) Research on the biology of childhood cancers, their causes, their prevention, and the avoidance of adverse late effects in children who are cured of cancer. The CCG conducts studies of all major childhood cancer types and requires the skills of all relevant clinical and basic science disciplines. At each of the 34 full member and 78 affiliate member institutions there is a team of investigators representing the diagnostic, therapeutic, laboratory, and supportive care disciplines required for state-of-the-art investigation of the cancers of children. The Group is directed by the Group Chairman, located at the M. D. Anderson Cancer Center in Houston, and is assisted by an experienced staff with diverse skills at the Group Operations Center in Arcadia, California. A staff of biostatisticians, database administrators, research data managers, systems analysts, communications specialists, and administrative personnel, assists the Group Chairman and the Director of Group-wide Operations in meeting the operational and administrative support needs of the Group's research activities. This application is for continuing support of all activities for which the Group Chairman is responsible. It includes the research plans and budget needs of the Group Chairman's Office, the Group Administration Offices, and the Statistics and Data Center. The application requests administrative and travel support for the major standing committees with Group-wide responsibilities. These include nine Disease Strategy Groups, which recommend strategic issues for study for each major type of childhood cancer; seven Scientific Committees, which provide expertise in specific areas of science; eight Modality or Discipline Committees, which provide expertise in specific clinical disciplines; eight Centralized Reference and Resource Laboratories, which provide technical laboratory work and biology research in support of specific Group studies, and three Review Centers, which review specimens, films, and data to assure Group- wide quality control. Funds are requested to continue the Cooperative Group Outreach Program (CGOP). which is the major source of support for selected affiliate member institutions and to continue the Group's on-site Audit and quality assurance activities. Developmental Funds are requested to enable the Group Chairman to respond to unanticipated needs and to new initiatives of scientific merit.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA013539-23
Application #
2086154
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1976-12-01
Project End
1998-11-30
Budget Start
1994-12-01
Budget End
1995-11-30
Support Year
23
Fiscal Year
1995
Total Cost
Indirect Cost
Name
National Childhood Cancer Foundation
Department
Type
DUNS #
624124301
City
Arcadia
State
CA
Country
United States
Zip Code
91006
Bouffet, Eric; Allen, Jeffrey C; Boyett, James M et al. (2016) The influence of central review on outcome in malignant gliomas of the spinal cord: the CCG-945 experience. J Neurosurg Pediatr 17:453-9
Dupuis, L Lee; Lu, Xiaomin; Mitchell, Hannah-Rose et al. (2016) Anxiety, pain, and nausea during the treatment of standard-risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the Children's Oncology Group. Cancer 122:1116-25
Mitchell, Hannah-Rose; Lu, Xiaomin; Myers, Regina M et al. (2016) Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study AALL0331. Int J Cancer 138:332-9
Hastings, Caroline; Gaynon, Paul S; Nachman, James B et al. (2015) Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (?200 × 10(9) /l) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children's Oncology Br J Haematol 168:533-46
Salzer, Wanda L; Jones, Tamekia L; Devidas, Meenakshi et al. (2015) Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group. Pediatr Blood Cancer 62:414-8
Linabery, Amy M; Erhardt, Erik B; Richardson, Michaela R et al. (2015) Family history of cancer and risk of pediatric and adolescent Hodgkin lymphoma: A Children's Oncology Group study. Int J Cancer 137:2163-74
Winter, Stuart S; Dunsmore, Kimberly P; Devidas, Meenakshi et al. (2015) Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer 62:1176-83
Linabery, Amy M; Li, Wenchao; Roesler, Michelle A et al. (2015) Immune-related conditions and acute leukemia in children with Down syndrome: a Children's Oncology Group report. Cancer Epidemiol Biomarkers Prev 24:454-8
Myers, Regina M; Balsamo, Lyn; Lu, Xiaomin et al. (2014) A prospective study of anxiety, depression, and behavioral changes in the first year after a diagnosis of childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Cancer 120:1417-25
Venkatramani, Rajkumar; Spector, Logan G; Georgieff, Michael et al. (2014) Congenital abnormalities and hepatoblastoma: a report from the Children's Oncology Group (COG) and the Utah Population Database (UPDB). Am J Med Genet A 164A:2250-5

Showing the most recent 10 out of 458 publications